Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Zebra Technologies (ZBRA) Numbers Signals, Lannett Company (LCI) FDA Green Light For Bioequivalent Diazepam Oral Solution

|Includes:LCI, Zebra Technologies Corporation (ZBRA) Zebra Technologies Corp. (NASDAQ:ZBRA)

ZBRA reported that it expects to report sales for the first quarter of 2014 in the range of $287,000,000 to $289,000,000, or 21% over the $236,937,000 in sales reported for the same period the prior year, while ZBRA's earnings are expected in a range of $0.79 to $0.82 per share, up approximately 74% from $0.46 per share for the first quarter of 2013.

ZBRA also announced that it will acquire Motorola's Enterprise business for $3.45 billion in an all-cash transaction.

ZBRA offers technologies that give a virtual voice to an organization's assets, people and transactions, enabling organizations to unlock greater business value.

More about Zebra Technologies Corp. (ZBRA) at

** Lannett Company, Inc. (NYSEMKT:LCI)

LCI reported that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application for Diazepam Oral Solution (Concentrate), 5 mg/mL, a Schedule C-IV controlled drug.

Diazepam Oral Solution (Concentrate), 5 mg/mL, is therapeutically equivalent to the reference listed drug, Diazepam Intensol Oral Solution (Concentrate), 5 mg/mL, of Roxane Laboratories, Inc.

LCI develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

More about Lannett Company, Inc. (LCI) at


Read Full Disclaimer at

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Stocks: ZBRA, LCI